Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus

doi:10.4239/wjd.v5.i5.678

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6577)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

456

WORD

275

HTML

3650

Figures (1-6)

195

Sum=4576

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1188

Download

813

Sum=2001

Oct 15, 2014 (publication date) through May 7, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Oct 15, 2014; 5(5): 678-688
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.678

Full Size Figure Download Figure

Figure 3 Kaplan-Meier survival curves in accordance with the tertiles of hepatocyte growth factor. The survival curves shows a worsened result for subjects with elevated hepatocyte growth factor (HGF) concentrations[45].

Citation: Konya H, Miuchi M, Satani K, Matsutani S, Tsunoda T, Yano Y, Katsuno T, Hamaguchi T, Miyagawa JI, Namba M. Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. World J Diabetes 2014; 5(5): 678-688
URL: https://www.wjgnet.com/1948-9358/full/v5/i5/678.htm
DOI: https://dx.doi.org/10.4239/wjd.v5.i5.678